Sono-Tek Corp. 10-Q Summary: Period Ended August 31, 2008
Business Context and Reporting Period
Sono-Tek Corporation (SONO) is a smaller reporting company specializing in ultrasonic atomizing nozzles and coating systems for electronics, medical, and industrial applications. This Form 10-Q covers the quarterly period ended August 31, 2008, and the six-month period ended on that date. The company is headquartered in Milton, NY, and operates as a non-accelerated filer.
Key Financial Metrics
| Metric | Six Months Ended Aug 31, 2008 | Six Months Ended Aug 31, 2007 | Three Months Ended Aug 31, 2008 |
|---|---|---|---|
| Net Sales | $3,226,003 | $2,647,166 | $1,605,482 |
| Gross Profit | $1,547,075 | $1,259,282 | $758,211 |
| Gross Margin | 48% | 48% | 47% |
| Operating Loss | $(322,438) | $(52,942) | $(183,167) |
| Net Loss | $(307,754) | $31,984 (Income) | $(177,296) |
| Cash and Equivalents (End of Period) | $1,285,399 | $2,223,514 | $1,285,399 |
| Working Capital | $3,588,696 | $4,059,720 | $3,588,696 |
| Total Debt (Current + Long Term) | $37,195 | $51,537 | $37,195 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 22% ($579,000) for the six months ended August 31, 2008, compared to the prior year. This growth was driven by increased sales of fluxer units, nozzles, stent coaters, and spray dryer units.
- Profitability Decline: Despite revenue growth, the company reported a net loss of $307,754 for the six-month period, compared to a net income of $31,984 in the same period last year. The operating loss widened from $52,942 to $322,438.
- Expense Increases: Operating expenses rose significantly. Marketing and selling expenses increased by $350,000 due to sales force reorganization and increased trade show participation. Research and development costs rose by $49,000 due to added engineering personnel. General and administrative costs increased by $158,000, partly due to higher stock-based compensation ($84,149 vs. $19,838).
- Cash Flow: Operating cash flow turned negative, using $943,367 compared to providing $32,009 in the prior year. This was primarily due to the net loss, a $202,000 increase in accounts receivable, and a $437,000 increase in inventory.
Outlook, Risks, and Management Commentary
Management attributes the expense increases to strategic investments in business development, including the reorganization of sales into Strategic Business Units and the expansion of the WideTrack coating system into new markets (glass, textiles, solar, fuel cells). The company continues to focus on the medical device market, specifically drug-coated stents.
Risks and Contingencies:
- Embezzlement Recovery: The company is recovering funds from a former employee who misappropriated approximately $250,000. While 74% has been recovered, the remaining balance is reserved against as collectibility is questionable.
- Liquidity: Working capital decreased by approximately $471,000 to $3.59 million. However, the current ratio remains strong at 6.06 to 1.
- Forward-Looking Statements: Management notes that future profitability depends on the successful implementation of new product development and market expansion, which involves inherent uncertainties.
Investor Verification Checklist
- Verify the sustainability of the 22% revenue growth given the significant increase in operating expenses and the resulting net loss.
- Monitor the collection status of the remaining 26% of the $250,000 embezzlement recovery.
- Assess the impact of the $437,000 inventory buildup on future cash flow and potential obsolescence risks.
- Review the effectiveness of the new sales force structure in converting increased marketing spend into profitable sales.
- Confirm the company's ability to maintain liquidity as cash reserves declined by over $1 million in six months.